论文部分内容阅读
虽然聚乙二醇干扰素(PEG-INF)治疗丙型肝炎期间常引起骨髓抑制,但白细胞计数的下降与发生感染风险的关系仍未确定。一项随机、平行、多中心Ⅲ期IDEAL(Individualized Dosing Efficacy vs Flat Dosing to Assess Optimal Pegylated Interferon Therapy)研究,旨在确定PEGINF/利巴韦林治疗丙型肝炎期间感染发生的概率和危险因素。3 070例未曾接受治疗的慢性HCV-Ⅰ型患者接受48周的PEG-IFN-α-2b每周1.5μg/kg或1μg/kg、或PEGIFN-α-2a180μg/周联合利巴韦林治疗。每2~6周检查白细胞计数,当中性粒细胞计数<0.75×109/L时,减少干扰素剂量;<0.5×109/L时,停用干扰素。禁用粒细胞集落刺
Although peginterferon (PEG-INF) often causes myelosuppression during treatment of hepatitis C, the relationship between the decline in white blood cell count and the risk of infection remains uncertain. A randomized, parallel, multicenter IDEAL (Individualized Dosing Efficacy vs Flat Dosing to Assess Optimal Pegylated Interferon Therapy) study was conducted to determine the probability and risk factors for PEGINF / ribavirin infection during hepatitis C infection. 3 070 untreated chronic HCV-I patients received 48 weeks of PEG-IFN-α-2b 1.5 μg / kg or 1 μg / kg weekly, or PEGIFN-α-2a 180 μg / week combined with ribavirin. Every 2 to 6 weeks to check the white blood cell count, when the neutrophil count <0.75 × 109 / L, reducing the dose of interferon; <0.5 × 109 / L, disable the interferon. Disable granulocyte colony